0001551152-26-000017
SEC filingAbbVie delivered 12.4% revenue growth to $15.0B with gross margin expansion to 71.9%, driving 15.4% higher gross profit, though net income declined 46.0% to $695M amid non-operating pressures.
AbbVie's Q1 2026 results showed robust top-line growth with revenue reaching $15.0 billion, up 12.4% from $13.3 billion in the prior year quarter. This expansion stemmed from the company's diversified portfolio, where operational strengths in areas like aesthetics provided resilience. Gross profit climbed 15.4% to $10.8 billion, expanding the gross margin to 71.9% from the prior period's level. This improvement reflects favorable revenue mix and scale efficiencies, enabling better coverage of fixed costs despite ongoing patent and pricing dynamics in the biopharma sector.
Operating income advanced 6.9% to $4.0 billion, maintaining a solid 26.6% operating margin. The moderated pace relative to gross profit growth indicates contained operating expense pressures, allowing the company to convert topline gains into bottom-line profitability at the operating level. However, net income dropped sharply 46.0% to $695 million from $1.3 billion, with diluted EPS falling to $0.39 from $0.72. This decline highlights the impact of non-operating items below the line, which offset core operational progress and underscore the volatility from external factors like regulatory and legal developments in pharmaceuticals.